To our knowledge, there is currently no report in Egypt assessing the impact of EGFR classical mutations on advanced NSCLC by case–control research, which is preferable to cross-sectional studies in respect of risk factor evaluation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.